An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday.
Trending
- Penn State’s Kiyomi McMiller believes she’s the best, and she’s eager to show you why
- Why Washington Commanders QB Jayden Daniels needs to sit the rest of the season
- Google to buy carbon credits from massive Amazonian reforestation project
- Amazon launches an AI-powered Kindle Translate service for ebook authors
- Sam Altman says he doesn’t want the government to bail out OpenAI if it fails
- Ford execs reportedly discuss ending the F-150 Lightning
- Sora for Android saw nearly half a million installs on its first day
- Viral Video Shows ICE Agents Dragging Out And Arresting Preschool Teacher In Chicago
Experimental therapy gantenerumab fails to slow or improve Alzheimer’s memory loss in clinical trials
